Allakos Inc. (NASDAQ:ALLK – Get Free Report) CFO Harlan Baird Radford sold 87,064 shares of Allakos stock in a transaction on Friday, June 28th. The stock was sold at an average price of $1.01, for a total value of $87,934.64. Following the sale, the chief financial officer now directly owns 204,390 shares of the company’s stock, valued at $206,433.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Allakos Stock Down 4.5 %
NASDAQ ALLK traded down $0.04 during trading on Tuesday, reaching $0.84. 756,866 shares of the stock traded hands, compared to its average volume of 1,054,483. The stock’s 50-day moving average price is $1.20 and its 200 day moving average price is $1.49. Allakos Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $5.64.
Allakos (NASDAQ:ALLK – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.09). Analysts expect that Allakos Inc. will post -1.24 EPS for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on Allakos
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Aristides Capital LLC bought a new stake in shares of Allakos in the fourth quarter worth $153,000. BNP Paribas Financial Markets lifted its position in shares of Allakos by 1,041.1% in the first quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company’s stock worth $259,000 after purchasing an additional 187,640 shares in the last quarter. Pennant Investors LP bought a new stake in shares of Allakos in the fourth quarter worth $508,000. GSA Capital Partners LLP bought a new stake in shares of Allakos in the first quarter worth $929,000. Finally, Ikarian Capital LLC lifted its position in shares of Allakos by 293.4% in the first quarter. Ikarian Capital LLC now owns 932,675 shares of the company’s stock worth $1,175,000 after purchasing an additional 695,619 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.
About Allakos
Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
Featured Articles
- Five stocks we like better than Allakos
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- RXO Shares Surge Following New Acquisition Deal
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What is a Death Cross in Stocks?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.